Health Catalyst (NASDAQ:HCAT) vs. Evaxion A/S (NASDAQ:EVAX) Head to Head Comparison

Health Catalyst (NASDAQ:HCAT) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Analyst Ratings

This is a summary of current recommendations for Health Catalyst and Evaxion A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1	8	5	0	2.29
Evaxion A/S	1	0	3	1	2.80

Health Catalyst presently has a consensus target price of $4.36, indicating a potential upside of 76.31%. Evaxion A/S has a consensus target price of $12.33, indicating a potential upside of 144.71%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Health Catalyst.

Insider and Institutional Ownership

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 2.6% of Health Catalyst shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Health Catalyst and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-34.05%	-6.67%	-3.21%
Evaxion A/S	N/A	-68.82%	-24.12%

Risk & Volatility

Health Catalyst has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Earnings and Valuation

This table compares Health Catalyst and Evaxion A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$316.06 million	0.55	-$69.50 million	($1.59)	-1.56
Evaxion A/S	$7.65 million	5.49	-$10.57 million	($0.39)	-12.92

Evaxion A/S has lower revenue, but higher earnings than Health Catalyst. Evaxion A/S is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Summary

Evaxion A/S beats Health Catalyst on 8 of the 15 factors compared between the two stocks.

About Health Catalyst

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.